Welcome to our dedicated page for SeaStar Medical Holding SEC filings (Ticker: ICU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SeaStar Medical Holding Corporation (Nasdaq: ICU) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy statements, and other documents filed with the U.S. Securities and Exchange Commission. These filings give investors detailed information about SeaStar Medical’s commercial-stage healthcare business built around its Selective Cytopheretic Device (SCD) therapy and QUELIMMUNE (SCD-PED) product for pediatric acute kidney injury (AKI).
Through Form 8-K current reports, SeaStar Medical discloses material events such as the recommendation of an independent Data Safety Monitoring Review Board to continue the NEUTRALIZE-AKI pivotal trial with zero device-related safety issues, changes in executive leadership, and corporate actions like the approval and implementation of a 1-for-10 reverse stock split to adjust the company’s share structure while maintaining its Nasdaq listing. These filings also describe adjustments to clinical trial enrollment targets and other operational updates.
The company’s DEF 14A proxy statements provide details on matters submitted to stockholders, including proposals related to reverse stock splits and authorized share counts. They outline voting procedures, meeting logistics, and the rationale behind capital structure decisions. Together with other periodic and transactional filings, these documents help explain how SeaStar Medical manages its equity, governance, and financing as it advances SCD-based therapies.
On Stock Titan, SeaStar Medical’s filings are updated in near real time as they are posted to EDGAR. AI-powered summaries highlight the key points in complex filings, helping readers quickly understand topics such as trial-related disclosures, compensation arrangements for executives, and the impact of corporate actions on ICU common stock and ICUCW warrants. Users can also review filings that reference the company’s Breakthrough Device Designations, Humanitarian Device Exemption framework for QUELIMMUNE, and pivotal trial plans, gaining a structured view of how regulatory and clinical developments intersect with SeaStar Medical’s capital markets activity.
SeaStar Medical Holding Corporation is a commercial-stage healthcare company developing its Selective Cytopheretic Device (SCD) to treat life‑threatening hyperinflammatory conditions that drive acute and chronic organ failure. The SCD modulates over‑active neutrophils and monocytes via an extracorporeal membrane integrated into continuous renal replacement therapy systems.
In February 2024, the FDA approved the pediatric SCD therapy QUELIMMUNE under a Humanitarian Device Exemption for acute kidney injury due to sepsis, and commercial shipments began in July 2024. As of December 31, 2025, 10 hospitals had completed the required SAVE Surveillance Registry and purchased QUELIMMUNE, with early registry data in 21 patients showing no device‑related safety events and favorable 60‑ and 90‑day survival.
For adults, the pivotal NEUTRALIZE‑AKI trial in ICU patients with acute kidney injury on CRRT targets 339 subjects, with 181 enrolled as of March 21, 2026. The SCD platform has received multiple FDA Breakthrough Device Designations across acute kidney injury, cardiorenal and hepatorenal syndromes, end‑stage renal disease, and cardiac surgery–related systemic inflammation, supported by a patent estate of 17 U.S. and 29 foreign patents.
SeaStar Medical Holding Corporation reported much stronger 2025 results as it ramps commercialization of its QUELIMMUNE therapy. Net revenue rose to approximately $420 thousand in the fourth quarter from $67 thousand a year earlier, and to about $1.23 million for 2025 versus $135 thousand in 2024, reflecting a first full year of QUELIMMUNE sales and initial SCD research revenue. Quarterly net loss narrowed to roughly $2.9 million from $4.4 million, while full-year net loss improved to around $12.2 million from $24.8 million. Cash increased to $12.0 million as of December 31, 2025, compared with $1.8 million a year earlier. The company highlighted business progress, including adding top-ranked children’s hospitals to the QUELIMMUNE customer base, completing enrollment in the QUELIMMUNE SAVE pediatric post-marketing registry, surpassing the 50% enrollment milestone in the NEUTRALIZE-AKI pivotal trial in adults with acute kidney injury, and initiating a cardio-renal clinical trial using its Selective Cytopheretic Device therapy.
SeaStar Medical Holding Corp received an updated ownership report from investors Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC. As of December 31, 2025, they report beneficial ownership of 3,980,665 shares of common stock, equal to 9.99% of the class.
The position is entirely through six warrants held by Intracoastal. Three warrants are counted, while three additional warrants are contractually blocked from exercise above 9.99% or 4.99% ownership caps. Without these blocker provisions, their beneficial ownership would be 5,342,845 shares. The group states the holdings are not for changing or influencing control of SeaStar Medical.
SeaStar Medical Holding Corp director Kenneth Van Heel reported receiving a grant of restricted stock units (RSUs) under the company’s equity program. On February 6, 2026, he acquired 3,000 shares of common stock at a price of $0 as an award.
According to the filing, these RSUs will vest in full on February 6, 2027, meaning the shares become fully owned on that date if vesting conditions are met. After this grant, Van Heel beneficially owns 7,940 shares of SeaStar Medical common stock directly.
SeaStar Medical Holding Corp director John Neuman reported a stock-based award. On February 6, 2026, he received 3,000 shares of common stock at a stated price of $0, reported as an acquired transaction.
After this grant, Neuman beneficially owns 12,200 shares of SeaStar Medical common stock in direct form. The filing notes that the 3,000-share award represents restricted stock units (RSUs) that will vest in full on February 6, 2027.
SeaStar Medical Holding Corp director Vincent Bernadette N reported receiving 3,000 shares of common stock on February 6, 2026 under transaction code A, indicating an acquisition. The filing notes this represents a restricted stock unit (RSU) award that will vest in full on February 6, 2027. The shares were acquired at a stated price of $0 per share, leaving the director with 4,200 shares of beneficially owned common stock held directly after the grant.
SeaStar Medical Holding Corp director equity grant: Director Jennifer A. Baird received an award of 3,000 shares of common stock on February 6, 2026, reported at a price of $0 per share. After this grant, she beneficially owns 6,620 shares of the company’s common stock in direct ownership.
The 3,000-share award is structured as restricted stock units (RSUs) that will vest in full on February 6, 2027, meaning the shares are subject to a one-year service-based vesting period before becoming fully owned and freely transferable, subject to any company trading policies.
SeaStar Medical Holding Corp executive Towne Bradford K reported receiving 7,500 shares of common stock as a stock-based award. The shares, reported at a price of $0 per share, increased the executive's directly held stake to 9,050 shares.
The award is in the form of restricted stock units that vest in three equal installments on the first, second and third anniversaries of February 6, 2026. Towne Bradford K serves as the company's Principal Accounting Officer.
SeaStar Medical Holding Corp’s Chief Medical Officer Kevin Chung reported receiving 15,000 shares of common stock as a restricted stock unit (RSU) award on February 6, 2026. The RSUs vest in equal installments on the first, second, and third anniversaries of that date. After this grant, Chung beneficially owned 20,819 shares directly.
SeaStar Medical Holding Corp disclosed that its Chief Executive Officer, Eric Schlorff, received an award of 30,000 shares of common stock in the form of restricted stock units on February 6, 2026, at a grant price of $0 per share.
The RSU award vests in three equal installments on the first, second and third anniversaries of February 6, 2026. Following this grant, Schlorff beneficially owned 39,852 shares of SeaStar Medical common stock, held directly.